# Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

> **NCT04424303** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 152 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT04424303
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-04
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424303, "Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04424303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*